Katie E. Barber
OLE MISS FACULTY
Department:
School of Pharmacy
Email:
kbarber@umc.edu
Work Phone:
(601) 984-2061
Education
| Wayne State University, Infectious Diseases Pharmacokinetic/Pharmacodynamic Fellowship | 2014 |
| Detroit Medical Center, Infectious Diseases Pharmacy Residency | 2012 |
| Louisiana State University Health Sciences Center, Pharmacy Practice Residency | 2011 |
| South Carolina College of Pharmacy, PharmD, Pharmacy | 2010 |
Publications
Letter | |
| Barber KE, Rybak MJ, Sakoulas G, Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. The Journal of antimicrobial chemotherapy, 2015 Jan;70(1):311-3 | 2015 |
| Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ, Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. The Journal of antimicrobial chemotherapy, 2015 Apr;70(4):1272-3 | 2015 |
Journal Article | |
| Barber KE, Werth BJ, Rybak MJ, The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. The Journal of antimicrobial chemotherapy, 2015 Feb;70(2):505-9 | 2015 |
| Werth BJ, Barber KE, Tran N, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ, Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. The Journal of antimicrobial chemotherapy, 2015 Feb;70(2):489-93 | 2015 |
| Barber KE, King ST, Stover KR, Pogue JM, Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert review of anti-infective therapy, 2015 Mar;13(3):363-77 | 2015 |
| Smith JR, Barber KE, Raut A, Rybak MJ, β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrobial agents and chemotherapy, 2015 May;59(5):2842-8 | 2015 |
| Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ, Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial agents and chemotherapy, 2015 Aug;59(8):4497-503 | 2015 |
| Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ, Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Antimicrobial agents and chemotherapy, 2015 Sep;59(9):5529-34 | 2015 |
| Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ, Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrobial agents and chemotherapy, 2014 May;58(5):2541-6 | 2014 |
| Barber KE, Werth BJ, McRoberts JP, Rybak MJ, A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2014 May;58(5):2989-92 | 2014 |
| Werth BJ, Barber KE, Ireland CE, Rybak MJ, Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrobial agents and chemotherapy, 2014 Jun;58(6):3177-81 | 2014 |
| Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ, Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. The Journal of antimicrobial chemotherapy, 2014 Aug;69(8):2148-54 | 2014 |
| Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ, Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. The Journal of antimicrobial chemotherapy, 2014 Nov;69(11):3006-10 | 2014 |
| Barber KE, Ireland CE, Bukavyn N, Rybak MJ, Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infectious diseases and therapy, 2014 Jun;3(1):35-43 | 2014 |
| Smith JR, Claeys KC, Barber KE, Rybak MJ, High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. Current infectious disease reports, 2014 Oct;16(10):429 | 2014 |
| Pogue JM, Mann T, Barber KE, Kaye KS, Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert review of anti-infective therapy, 2013 Apr;11(4):383-93 | 2013 |
| Rybak JM, Barber KE, Rybak MJ, Current and prospective treatments for multidrug-resistant gram-positive infections. Expert opinion on pharmacotherapy, 2013 Oct;14(14):1919-32 | 2013 |
| Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ, β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. The Journal of antimicrobial chemotherapy, 2015;70(6):1738-43 | |